HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo

Combinations of proteasome inhibitors and histone deacetylases (HDAC) inhibitors appear to be the most potent to produce synergistic cytotoxicity in preclinical trials. We have recently confirmed that L-carnitine (LC) is an endogenous HDAC inhibitor. In the current study, the anti-tumor effect of LC...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Huang, Hongbiao, Liu, Ningning, Yang, Changshan, Liao, Siyan, Guo, Haiping, Zhao, Kai, Li, Xiaofen, Liu, Shouting, Guan, Lixia, Liu, Chunjiao, Xu, Li, Zhang, Change, Song, Wenbin, Li, Bing, Tang, Ping, Dou, Q. Ping, Liu, Jinbao
Format: Artigo
Langue:Inglês
Publié: Public Library of Science 2012
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3527572/
https://ncbi.nlm.nih.gov/pubmed/23285100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0052576
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires